A cell-based cancer immunotherapy that utilizes a nanoparticle developed at UCF to stimulate a patient’s natural cancer-killing cells has just received the green light to proceed directly into a Phase II clinical trial.
A cell-based cancer immunotherapy that utilizes a nanoparticle developed at UCF to stimulate a patient’s natural cancer-killing cells has just received the green light to proceed directly into a Phase II clinical trial.